172 related articles for article (PubMed ID: 28146267)
1. Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.
Gao R; Liang JH; Wang L; Zhu HY; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Yang T; Li JY; Xu W
Br J Haematol; 2017 Apr; 177(1):95-105. PubMed ID: 28146267
[TBL] [Abstract][Full Text] [Related]
2. Low T3 syndrome as a predictor of poor prognosis in chronic lymphocytic leukemia.
Gao R; Chen RZ; Xia Y; Liang JH; Wang L; Zhu HY; Zhu Wu J; Fan L; Li JY; Yang T; Xu W
Int J Cancer; 2018 Aug; 143(3):466-477. PubMed ID: 29457831
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
5. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
6. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
7. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
[TBL] [Abstract][Full Text] [Related]
8. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
10. Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma.
Xue LG; Shen HR; Gao R; Du KX; Xing TY; Wang WT; Wang L; Li JY; Liang JH; Xu W
Ann Hematol; 2023 Apr; 102(4):851-862. PubMed ID: 36735075
[TBL] [Abstract][Full Text] [Related]
11. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
12. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
13. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
Montalbán C; Díaz-López A; Dlouhy I; Rovira J; Lopez-Guillermo A; Alonso S; Martín A; Sancho JM; García O; Sánchez JM; Rodríguez M; Novelli S; Salar A; Gutiérrez A; Rodríguez-Salazar MJ; Bastos M; Domínguez JF; Fernández R; Gonzalez de Villambrosia S; Queizan JA; Córdoba R; de Oña R; López-Hernandez A; Freue JM; Garrote H; López L; Martin-Moreno AM; Rodriguez J; Abraira V; García JF;
Br J Haematol; 2017 Mar; 176(6):918-928. PubMed ID: 28106247
[TBL] [Abstract][Full Text] [Related]
14. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma.
Gao R; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Yang T; Xu W
Int J Cancer; 2018 Oct; 143(8):1884-1895. PubMed ID: 29744861
[TBL] [Abstract][Full Text] [Related]
15. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
Wen J; Zhou J; Liu Z; Liu T; Xu C
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
[TBL] [Abstract][Full Text] [Related]
17. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
18. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
19. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of Different Staging Systems and Prognostic Analysis in 68 Cases of Primary Intestinal Diffuse Large B Cell Lymphoma].
Wang X; Wang CY; Xu W; Yang HL; Zhao HF; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):52-60. PubMed ID: 30738447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
